WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program

Key Points

• WVE-008 is aimed at genetically defined liver disease: WAVE plans to file a clinical trial application in Q4 2026 for its RNA-editing candidate targeting the PNPLA3 I148M variant. Preclinical studies showed editing and reduced lipid accumulation, but the results have not been demonstrated in patients.
• WVE-007 is advancing in clinical studies: In earlier data, a single dose suppressed Activin E for at least seven months and was associated with reductions in total and visceral fat. WAVE expects to start a maintenance trial and report data from the Phase I 600-mg cohort this year.
• Other platform programs remain preclinical: WAVE reported mouse data on delivery beyond the liver and on bifunctional oligonucleotides targeting LPA and PCSK9. It also expects to report WVE-006 trial data later this year.

WAVE Life Sciences NASDAQ: WVE used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing updates on its RNA interference, extrahepatic delivery and bifunctional oligonucleotide platforms.

Chief Executive Officer Paul Bolno said the company’s approach combines genetic target selection with proprietary oligonucleotide chemistry designed to enable RNA silencing, editing and upregulation. Wave said it expects to file a clinical trial application, or CTA, for WVE-008 in the fourth quarter of 2026.

PNPLA3 Program Targets Genetically Defined Liver Disease

WVE-008 is a GalNAc-conjugated RNA editing oligonucleotide intended to correct the PNPLA3 I148M variant, which the company described as a major genetic risk factor for progressive liver disease. The variant has been associated with metabolic dysfunction-associated steatotic liver disease, or MASLD; metabolic dysfunction-associated steatohepatitis, or MASH; alcohol-associated liver disease; cirrhosis; and hepatocellular carcinoma.

Arun Sanyal, professor of medicine and physiology and molecular pathology at Virginia Commonwealth University, said PNPLA3 I148M is linked to excess liver fat, fibrosis progression and liver-related mortality. He estimated that approximately 18 million people in the United States carry the mutation and said its prevalence varies considerably across populations, including substantial representation in Latin America.

According to Sanyal, the mutation impairs triglyceride processing in the liver and can also affect retinol metabolism in hepatic stellate cells, which contribute to fibrosis. He said the effects may be particularly relevant in older patients and those with type 2 diabetes.

Wave said more than 9 million people in the United States and Europe who have liver disease are homozygous for the I148M variant. Chief Scientific Officer Erik Ingelsson said the company’s goal is to edit at least 50% of PNPLA3 transcripts in the liver, aiming to create a functional state resembling heterozygous carriers, who the company said have lower liver-related risk than homozygous carriers.

Ingelsson contrasted Wave’s editing approach with PNPLA3 silencing. He said the wild-type PNPLA3 protein has roles in lipid and retinol metabolism, and presented preclinical findings in human liver models suggesting that silencing PNPLA3 can worsen steatosis, inflammation-induced cell death and fibrotic responses. Wave believes correcting the disease-associated variant could preserve normal PNPLA3 function while addressing the mutant protein’s effects.

The company reported preclinical data showing that WVE-008 produced on-target editing in primary human hepatocytes, reduced lipid accumulation in human hepatocyte models, and distributed across liver zones in mice. Wave also reported uptake and more than 60% editing in mouse hepatic stellate cells using a surrogate PNPLA3 editing compound. These findings have not yet been demonstrated in patients.

During the question-and-answer session, management said the initial clinical approach would use genotype-based enrollment and seek to assess editing, biomarker changes and physiological effects efficiently. Company executives did not provide a detailed trial design, saying further details would be shared after the CTA filing and trial initiation.

SpiNA RNAi Platform and WVE-007 Update

Chief Technology Officer Chandra Vargeese discussed Wave’s stereopure interfering nucleic acid, or SpiNA, design platform. The company said its controlled backbone stereochemistry and proprietary chemistry can increase loading into the AGO2 protein complex, which is involved in RNA-mediated silencing.

Wave presented preclinical comparisons involving transthyretin, PCSK9 and other targets, saying SpiNA designs showed greater potency and longer duration than reference siRNA constructs. Vargeese said the chemistry is not sequence-dependent and has translated across multiple targets.

The company highlighted WVE-007, an siRNA targeting INHBE that is being studied in the Phase II INLIGHT trial. Wave said prior clinical data in otherwise healthy participants showed dose-dependent suppression of serum Activin E lasting at least seven months after a single dose. The company also reported reductions in total and visceral fat and waist circumference, with lean mass stabilization and what it characterized as a favorable safety profile.

Wave said preclinical diet-induced obesity mouse studies showed weight loss comparable to semaglutide following a single dose of its INHBE SpiNA. In lean mice, however, the company said it did not observe a weight-loss effect, which management said supports its view that baseline adiposity may influence the mechanism’s effects.

Wave expects to initiate a maintenance trial for WVE-007 and share data from the 600-milligram cohort of its Phase I INLIGHT study this year.

Extrahepatic Delivery and Bifunctional Constructs

Vargeese also described Wave’s PN conjugate platform, which is intended to extend oligonucleotide delivery beyond hepatocytes. The company reported mouse data suggesting certain PN-conjugated designs could achieve silencing in adipose tissue, in both liver and adipose tissue, and in kidney cell types.

For an undisclosed cardiometabolic target referred to as “Target A,” Wave said it observed sustained knockdown in liver and white adipose tissue for up to three months after a single dose in mice. It also reported preclinical kidney data showing reductions in SOD1 messenger RNA.

In addition, Wave presented bifunctional oligonucleotide programs designed to modulate two targets with one construct. In transgenic mice, the company said a bifunctional LPA-PCSK9 construct reduced both circulating lipoprotein(a) and PCSK9 at levels comparable to the respective single-target molecules. Wave said it plans to present additional bifunctional SpiNA data in 2027.

Finally, Wave reiterated plans to report data from the 600-milligram cohort of its RestorAATion-2 clinical trial of WVE-006, its RNA editing candidate for alpha-1 antitrypsin deficiency, later this year.

About WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.